Meeting
2017 ASCO Annual Meeting
Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy.
Authors
Maura L. Gillison
The Ohio State University, Columbus, OH
Maura L. Gillison , George R. Blumenschein Jr., Jérôme Fayette , Joel Guigay , A. Dimitrios Colevas , Lisa Licitra , Kevin Harrington , Stefan Kasper , Everett E. Vokes , Caroline Even , Francis P. Worden , Nabil F. Saba , Lara Carmen Iglesias Docampo , Robert I. Haddad , Tamara Rordorf , Naomi Kiyota , Makoto Tahara , Mark John Lynch , Justin Kopit , Robert L. Ferris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02105636
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6019)
DOI
10.1200/JCO.2017.35.15_suppl.6019
Abstract #
6019
Poster Bd #
7
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
First Author: Robert L. Ferris
Poster
2018 ASCO Annual Meeting
Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.
First Author: Nabil F. Saba
Poster
2023 ASCO Annual Meeting
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
First Author: Douglas Adkins
Poster
2017 ASCO Annual Meeting
Cost-effectiveness of nivolumab for treatment of platinum-resistant recurrent or metastatic squamous cell carcinoma of the head and neck.
First Author: Kate Carroll